An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Cosette Pharmaceuticals Launches Betaine Anhydrous Powder, AB-rated to Cystadane® (betaine anhydrous for oral solution)
Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Cosette Pharmaceuticals has announced the acquisition of US marketing rights for Betaine Anhydrous for Oral Solution from ANI Pharmaceuticals (ANIP), beginning immediate shipping to customers. This product provides an important treatment option for patients suffering from homocystinuria, a rare genetic disorder. The CEO of Cosette, Apurva Saraf, emphasized that this launch reflects the company's commitment to innovation and partnership in the pharmaceutical industry. The initiative aims to support U.S. patients and healthcare providers with a safe and effective medication.
Positive
Acquisition of US marketing rights for Betaine Anhydrous enhances product portfolio.
Launch addresses unmet medical needs for patients with homocystinuria.
Immediate shipping to customers demonstrates operational readiness and commitment.
Negative
None.
Launch offers important and affordable alternative for patients
BRIDGEWATER, N.J.--(BUSINESS WIRE)--
Cosette Pharmaceuticals, Inc. ("Cosette") has obtained the US marketing rights to Betaine Anhydrous for Oral Solution 180gm (“Betaine”) in an agreement with ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) and commenced shipping (NDC #0713-0352-81) to customers this week.
Apurva Saraf, President and CEO of Cosette Pharmaceuticals (Photo: Business Wire)
Apurva Saraf, President and CEO of Cosette, stated "This launch is further evidence of Cosette’s ability to partner globally and bring important drugs to the market, and furthers our transformation into a specialty pharmaceutical company. We stay true to our firm belief of Innovating Every Day, to be a trusted partner of choice, and to continue the important work of serving U.S. patients and prescribers.”
Betaine is used by patients with homocystinuria, a rare genetic condition where too much homocysteine builds up in the body. This launch will provide patients with homocystinuria, and the healthcare providers delivering care to those patients, with a safe, efficacious and accessible treatment option.
See the Full Prescribing Information and Instructions for Use for Betaine Anhydrous for Oral Solution, 180 grams. www.dailymed.com
Cystadane® is registered trademark of Recordati Rare Diseases
About Cosette Pharmaceuticals, Inc.:
Cosette Pharmaceuticals, Inc. is a US-based, fully integrated pharmaceutical company with capabilities in product development, manufacturing, and commercial operations. Cosette has a fast-growing portfolio of branded pharmaceuticals consisting of products in the cardiology, women’s health and migraine markets. Cosette has a long history in quality manufacturing of complex dosage forms including topical creams, ointments, oral liquids/solutions and suppositories, which has led to consistent supply to customers and commercialization success. Cosette has corporate and manufacturing facilities in New Jersey and North Carolina, and is supported by more than 350+ dedicated employees across all functional areas. Cosette is backed by Avista Capital Partners, a healthcare focused private equity firm. www.cosettepharma.com
What is the significance of ANI Pharmaceuticals (ANIP) in the Betaine Anhydrous launch?
ANI Pharmaceuticals (ANIP) provided the US marketing rights for Betaine Anhydrous, enabling Cosette Pharmaceuticals to launch this important medication.
Who are the intended patients for Betaine Anhydrous for Oral Solution?
Betaine Anhydrous for Oral Solution is intended for patients with homocystinuria, a rare genetic condition characterized by high levels of homocysteine.
When did Cosette Pharmaceuticals start shipping Betaine Anhydrous?
Cosette Pharmaceuticals commenced shipping Betaine Anhydrous for Oral Solution to customers this week.
